Acuitas Investments LLC Buys 56,300 Shares of AngioDynamics, Inc. $ANGO

Acuitas Investments LLC increased its stake in AngioDynamics, Inc. (NASDAQ:ANGO) by 12.7% in the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 498,530 shares of the medical instruments supplier’s stock after acquiring an additional 56,300 shares during the quarter. AngioDynamics makes up about 3.6% of Acuitas Investments LLC’s portfolio, making the stock its 5th biggest holding. Acuitas Investments LLC owned 1.21% of AngioDynamics worth $5,569,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. State of Wyoming increased its stake in shares of AngioDynamics by 53.6% during the third quarter. State of Wyoming now owns 4,749 shares of the medical instruments supplier’s stock worth $53,000 after purchasing an additional 1,658 shares in the last quarter. State of Alaska Department of Revenue purchased a new stake in AngioDynamics during the 3rd quarter worth approximately $25,000. Washington Trust Advisors Inc. acquired a new position in shares of AngioDynamics during the third quarter valued at approximately $27,000. Rhumbline Advisers lifted its position in shares of AngioDynamics by 4.3% in the second quarter. Rhumbline Advisers now owns 61,337 shares of the medical instruments supplier’s stock valued at $608,000 after acquiring an additional 2,510 shares in the last quarter. Finally, Invesco Ltd. boosted its stake in shares of AngioDynamics by 2.2% in the second quarter. Invesco Ltd. now owns 122,596 shares of the medical instruments supplier’s stock worth $1,216,000 after acquiring an additional 2,667 shares during the last quarter. 89.43% of the stock is owned by hedge funds and other institutional investors.

AngioDynamics Stock Performance

Shares of NASDAQ ANGO opened at $10.71 on Wednesday. The stock’s 50-day simple moving average is $10.73 and its 200-day simple moving average is $11.54. The firm has a market capitalization of $441.47 million, a PE ratio of -15.98 and a beta of 0.48. AngioDynamics, Inc. has a fifty-two week low of $8.36 and a fifty-two week high of $13.99.

Wall Street Analyst Weigh In

ANGO has been the subject of several recent research reports. Wall Street Zen downgraded AngioDynamics from a “buy” rating to a “hold” rating in a research note on Sunday, December 21st. Weiss Ratings reiterated a “sell (d-)” rating on shares of AngioDynamics in a research report on Wednesday, January 21st. Finally, Zacks Research upgraded shares of AngioDynamics from a “hold” rating to a “strong-buy” rating in a research report on Friday, January 9th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, AngioDynamics has an average rating of “Moderate Buy” and a consensus target price of $19.33.

AngioDynamics Company Profile

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.